Genomic Data Annotation System for Polygenic Risk Prediction

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current clinical genetic tests for polygenic conditions have low accuracy, particularly for non-European ancestry individuals, leading to false negatives and delayed detection of life-threatening conditions, as they primarily focus on coding regions and miss non-coding variants crucial for disease risk prediction.

Innovation Solution

A system that converts unannotated genomic data into a standardized format, matches it with annotation data from diverse sources, and generates annotated variant loci, providing a polygenic risk score and personalized disease prevention or treatment recommendations by integrating non-coding variant information and functional annotations.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If clinical genetic tests focus on coding regions only, then the test complexity and cost are reduced, but the measurement precision and reliability of disease risk prediction deteriorate due to missing non-coding variants

Engineering Contradiction:
Improvedisease risk prediction accuracyVSAvoidgenomic data analysis complexity
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The system segments the genome into coding and non-coding regions, and further segments non-coding regions into functional elements (promoters, enhancers, etc.). This segmentation allows comprehensive analysis of all genomic regions while organizing the complexity into manageable categories, thereby improving prediction accuracy without overwhelming computational burden

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The system introduces an intermediary layer of functional annotation data that bridges raw genomic sequences and disease risk predictions. This intermediary layer includes pre-computed functional scores and regulatory element annotations that simplify the interpretation of non-coding variants, improving accuracy while managing complexity through intermediate representation

Inventive Principle:
Principle #24Intermediary (Mediator)

2Adaptability or versatility

If clinical genetic tests use standardized annotation formats, then the ease of operation and data integration are improved, but the adaptability to diverse data sources and varying data qualities deteriorates

Engineering Contradiction:
Improvedata source compatibilityVSAvoiddata processing simplicity
Core Design Contradiction:
Adaptability or versatilityVSEase of operation

Solution Approach 1:

The system dynamically adjusts annotation parameters and filtering thresholds based on data source characteristics and quality metrics. Different data sources receive customized processing parameters while all outputs are standardized to a common format, thereby maintaining both adaptability to diverse sources and ease of operation through uniform output standards

Inventive Principle:
Principle #35Parameter changes

3Measurement precision

If polygenic risk scores are calculated using current methods, then the productivity and speed of genetic testing are maintained, but the measurement precision deteriorates due to low accuracy particularly for non-European ancestry individuals

Engineering Contradiction:
Improvepolygenic risk score accuracyVSAvoiddisease detection delay
Core Design Contradiction:
Measurement precisionVSLoss of time

Solution Approach 1:

The system performs preliminary actions by pre-computing functional annotations, regulatory element mappings, and population-specific parameter sets before actual risk calculation. This preliminary preparation enables faster and more accurate polygenic risk scoring for diverse populations without increasing real-time computational burden, thereby improving accuracy while maintaining speed

Inventive Principle:
Principle #10Preliminary action

Data Source

PatentUS20240112752A1Methods and systems for annotating genomic data
Publication Date: 2024.04.04 MARTINGALE LABS INC
  • US20240112752A1 patent drawing
  • US20240112752A1 patent drawing
  • US20240112752A1 patent drawing

AI summary

In variants, the method can include receiving a subject's unannotated genomic data, optionally generating annotated variant loci, and optionally determining a risk score for the subject. The method can function to: provide genomic data analysis to a user; predict disease risk; and/or provide recommendations for screenings, treatment, and/or lifestyle changes.